Here are the 10-Q quarterly reports from Ernexa Therapeutics Inc. (ERNA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. reported a $12.5 million net loss and $9.6 million of operating cash use for the nine months ended September 30, 2026. Its September 30 cash balance was $5.6 million, below the amount needed for its current operating plan and forecast cash needs for the next 12 months; management expects ATM access to cover a significant portion of the shortfall and is pursuing financing. For the same nine-month period, research and development expense was $6.578 million, versus $3.480 million a year earlier, primarily reflecting ERNA-101 study and manufacturing costs.
An independent preclinical ovarian-cancer mouse study found complete tumor clearance and long-term survival in 10 of 15 models (67%) treated with ERNA-101 plus PD-1 blockade; neither treatment alone produced complete clearance or durable survival. Ernexa is prioritizing ERNA-101 and has deprioritized ERNA-201 for near-term resources.
ATM sales generated approximately $3.7 million net as of September 30, 2026; on October 6, 2026, an additional 43,700 shares generated $0.1 million net. Nasdaq restored bid-price compliance on May 29, 2026. A mandatory panel monitor continues through May 5, 2027, and a bid-price deficiency during monitoring would trigger a delisting determination.
Ernexa Therapeutics Inc., a pre-clinical iMSC cell-therapy company, reported a six-month net loss of $9.5 million to June 30, 2026, driven by $4.7 million in research and development as it advances lead oncology candidate ERNA‑101 and autoimmune program ERNA‑201. General and administrative expense was $2.9 million and a $2.0 million goodwill impairment eliminated all goodwill.
Cash was approximately $5.0 million at June 30, 2026 and about $7.4 million by August 4, after a February public offering delivering $9.5 million in net proceeds and subsequent ATM sales of 461,851 shares for $3.7 million. Management notes this cash is below forecast needs for the next 12 months and plans to rely on remaining ATM capacity under a $50.0 million shelf. During the quarter Ernexa completed a 1‑for‑25 reverse stock split to regain Nasdaq bid‑price compliance and recognized a $41,000 gain from extinguished contingent consideration. An independently run preclinical study in July 2026 reproduced ERNA‑101’s complete tumor clearance and durable survival in ovarian cancer models, supporting an IND filing planned for 2026 and a first‑in‑human Phase 1 trial thereafter.
Ernexa Therapeutics, a preclinical synthetic iMSC cell therapy company, reported a first‑quarter 2026 net loss of $5.5 million, smaller than the $8.2 million loss a year earlier. Operating expenses rose to $5.6 million, including $1.9 million in research and development and $1.6 million in general and administrative costs, plus a $2.0 million goodwill impairment.
Ernexa ended March 31, 2026 with $9.2 million in cash, helped by a February public offering that generated approximately $10.5 million in gross proceeds from common stock, pre‑funded warrants and Milestone Warrants. Stockholders also approved a 1‑for‑25 reverse stock split, effective May 4, 2026, leaving 1,166,333 common shares outstanding as of May 8, 2026.
Management notes that April 30, 2026 cash of about $8.3 million is below projected 12‑month needs, but expects access to up to $9.2 million through a newly established at‑the‑market program under a $50 million shelf registration to address forecasted shortfalls, while it advances lead oncology candidate ERNA‑101 toward an IND and Phase 1 trial.
Ernexa Therapeutics Inc. reported Q3 2025 results with a net loss of $1.24 million, a sharp improvement from a loss of $26.60 million a year ago. Year‑to‑date net loss was $12.58 million versus $38.78 million in 2024. There was no revenue in Q3 2025, compared with $0.49 million in Q3 2024, reflecting the prior assignment of its customer contract to Factor Bioscience.
Operating expenses were stable to lower: research and development was $1.04 million (vs. $1.00 million), while general and administrative fell to $0.96 million (vs. $3.38 million), aided by the absence of prior-year lease and professional fee items. Other income included a $0.73 million gain from writing off time‑barred payables. Year‑to‑date other expense was driven by a $5.85 million non‑cash forward sales contract expense tied to a 2025 private placement.
Cash was $3.05 million as of September 30, 2025, up from $1.73 million at year‑end, after $7.20 million of gross proceeds from common stock and pre‑funded warrant sales in 2025 and repayment of $2.3 million promissory notes. The company used $5.87 million in operating cash year‑to‑date and states there is substantial doubt about its ability to continue as a going concern without additional capital. A 1‑for‑15 reverse stock split became effective on June 12, 2025; 7,848,889 common shares were outstanding as of November 7, 2025.
Ernexa Therapeutics is a preclinical synthetic allogeneic iMSC therapy company developing ERNA-101 (IL-7/IL-15–secreting) for oncology and ERNA-201 for inflammatory disorders. Management expects to complete IND-enabling studies and submit an IND in 2026 with a planned Phase I investigator-sponsored trial in the second half of 2026.
Financially, the company reported $4.3 million in cash and an accumulated deficit of $242.9 million. Net loss was $3.1 million for the quarter and $11.3 million for the six months, which includes a $5.8 million non-cash forward sales contract expense. Ernexa raised approximately $7.2 million gross from a private placement, completed a 1-for-15 reverse stock split and increased authorized common shares to 150 million. Management disclosed substantial doubt aboutgoing concern and stated additional financing will be required. Stockholders' equity was $4.4 million at period end and the company reports compliance with Nasdaq continued listing standards.